. Heterogeneity -including differences in cell size and growth rate -has been documented in replicating populations of M. tuberculosis previously 5, 6 . Rego and colleagues sought to investigate the molecular basis of this heterogeneity by studying a related mycobacterial species called Mycobacterium smegmatis, using a fluorescent dye called calcein to monitor heterogeneity.
Rego et al. observed that calcein was homogeneously distributed in a parental cell, but was acquired unevenly by the two daughter cells upon division. The ends of a bacterial cell are known as the old and new poles (Fig. 1) .
The authors noted that more calcein was distributed to the daughter cell that inherited the parental cell's new pole. Intriguingly, Rego and colleagues observed that these highly fluorescent daughter cells had increased sensitivity to the antibiotic rifampicin, which is used in tuberculosis treatment, compared with the daughter cells that had low fluorescence and inherited the parental cell's old pole.
The authors screened for genetic mutants that were defective in the generation of hetero geneous progeny by monitoring levels of calcein fluorescence. They found that the progeny of lamA-mutant bacteria were similarly fluorescent and similarly sensitive to antibiotic challenge. Rego et al. observed that, in comparison to wild-type bacteria, the lamAmutant bacteria showed deposition of newly synthesized cell-wall material to both poles of the cell that was more equal. The lamA gene is unique to the genus Mycobacterium.
The authors created a version of LamA protein whose location in the cell could be monitored by a fluorescent tag. LamA was observed at the site of bacterial cell-wall division. Using other tests, the authors established that LamA is part of the protein complex known as the 'divisome' that enables cell division, and found that LamA associates with the PonA1 protein, which is known to be involved in building the cell wall during replication.
Rego and colleagues' analysis indicates that
nfection with Mycobacterium tuberculosis, the mycobacterial species responsible for tuberculosis, is one of the leading causes of death from infectious disease, and a frequent cause of death 1 for people with HIV. The ability of M. tuberculosis to cope with a range of environmental extremes, as well as its capacity to overcome many host immune defences and drug regimens, is central to its success as a pathogen. One tactic used by M. tuberculosis to survive such challenges is the generation of heterogeneity -a process whereby bacterial cells divide to produce daughter cells that are genetically identical but exhibit physio logical differences. Heterogeneity within a bacterial population ensures that subsets of bacteria are better equipped to survive a wide range of environmental stresses. On page 153, Rego et al. 2 detail the genetic basis of a process that generates diversity and variable drug sensitivity in a replicating population of mycobacterial cells.
Bacteria in the M. tuberculosis population of an infected individual might have differential drug sensitivity, which can arise through three mechanisms 3 . 'Persistent' and 'resistant' bacteria arise from two of the three mechanisms, and these types of bacterium are the least sensitive to antibiotics. Persisters are present in extremely low numbers in all bacterial populations examined thus far 4 . They are usually non-replicating cells that have low metabolic activity and can survive exposure to antibiotic concentrations that kill the other cells in the bacterial population. Resistant bacteria have heritable traits derived from one or more mutations in genes whose products are required for maximum antibiotic efficacy. The acquisition of such mutations can lead to the generation of stable, drug-resistant bacterial strains.
A third type of reduced drug sensitivity can occur because some bacteria in a population have the capacity to survive transient exposure to antibiotic concentrations that would usually be lethal. This phenomenon, known as phenotypic tolerance, is promoted by the hetero geneity of a bacterial population. Moreover, this form of drug insensitivity is arguably the greatest hurdle to effective chemotherapy. . Rego et al. 2 investigated the molecular basis of this heterogeneity, starting with the observation that a fluorescent dye, calcein, is distributed unequally between the daughter cells of the species Mycobacterium smegmatis. The ends of a bacterial cell are called the old pole and the new pole. Rego and colleagues observed that, in wild-type cell division, the daughter cell that inherited the parental cell's old pole had low fluorescence and exhibited low sensitivity to antibiotic treatment, whereas the daughter cell that inherited the parental cell's new pole had high fluorescence and was sensitive to antibiotics. This type of differential sensitivity to antibiotics is called phenotypic tolerance. The authors found that a mutation in the gene lamA resulted in cell division that produced daughter cells with similar levels of fluorescence and similar sensitivity to antibiotic treatment. Rego et al. observed that, in dividing wild-type cells, newly synthesized cell-wall material (purple) is not added equally to the two poles, whereas in a lamA mutant, the cell-wall material is added more equally. 
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Diversity breeds tolerance
A gene has been identified that underpins the capacity of mycobacterial cells to divide to produce physiologically different daughter cells. This finding has implications for drug treatment of tuberculosis. See Letter p.153
C L A I R E T. R O B E R TS
E ach year, about 15 million babies worldwide are born prematurely 1 , of whom about 9% are extremely premature, born after fewer than 30 weeks of gestation 2 . Research to develop an artificial womb in which to house extremely premature babies began in the 1960s, but no such device has yet been implemented 3 . Difficulties include contamination of the fluid in which babies must be submerged, which can cause infection, and pressure imbalances in the fetal blood vessels and heart caused by the device that provides oxygen, which can lead to heart failure. Writing in Nature Communications, Partridge et al. 4 report a step in the right direction -the development of a fluid-filled 'Biobag' into which they delivered lambs born at a stage equivalent to extremely premature human infants.
The Biobag is a sealable polythene bag in which synthetic amniotic fluid containing antibiotics is circulated in a sterile environment, preventing infections (see Fig. 1 of the paper   4 ). The authors placed eight extremely premature lambs in Biobags immediately after birth, and connected blood vessels from the animals' umbilical cords to a specialized pumpless oxygenator device. Blood flow around the device is driven by the lamb's heart rather than by a pump, mimicking the rate of blood flow between the fetus and placenta in utero, and so preventing pressure imbalances in the fetal heart and blood vessels. In addition, immediate incubation in a closed fluid environment prevents a cascade of changes that normally occur when the newborn takes its first breath, filling the lungs with air. These changes lead to re-routing of the circulation such that oxygenation occurs through the lungs, rather than from the placenta through the umbilical cord. Thus, the Biobag permits retention of the fetal circulation -no mean feat.
Following birth, newborns no longer receive a continuous nutrient supply from the placenta, so the researchers provided nutrients intravenously. Some lambs also received insulin, which promotes fetal growth 5 and regulates blood glucose levels. These animals grew at a similar rate to controls that developed in utero. Extremely premature human infants typically grow more poorly than they would in utero, so this is an impressive result.
Lambs were grown in Biobags for up to four weeks, and it is possible that longer incubation times would be feasible. Although such survival is an aim of neonatal intensive care units, survival without disability is the ultimate goal. Encouragingly, incubated lambs showed near-normal heart function. Oxygen delivery to the fetus and levels of the oxygen-carrying LamA is required to modify the mycobacterial cell wall in such a way that, in a single round of replication, half the daughter cells exhibit phenotypic drug tolerance. The mechanisms responsible for this differential drug sensitivity remain to be determined. This genetically encoded capacity to generate heterogeneity at each round of replication could confer a huge advantage for the maintenance of M. tuberculosis populations under drug pressure. The authors observed that, when treated with antibiotics, lamA-mutant M. tuberculosis cells were killed at a more uniform rate than wild-type M. tuberculosis cells.
Why would a process enabling the generation of heterogeneity in bacterial progeny through the action of LamA be found in Mycobacterium species? We might think of drug tolerance and drug resistance as properties emergent from modern-day antibiotic usage, but antibiotics are natural products that are particularly abundant in soil microbes. Ancestral mycobacterial species inhabiting such environmental niches would have encountered many antibiotic molecules and experienced selective pressures to acquire mechanisms of tolerance and resistance long before bacteria such as M. tuberculosis needed to evolve in response to modern chemotherapy.
Understanding the basis of heterogeneity might provide insight into the interplay between host immune-derived pressures and their effect on current antituberculosis treatments. Rego and colleagues' research reveals one mechanism by which heterogeneity might be generated among replicating M. tuberculosis, but it is certainly not the only mechanism, and the situation is undoubtedly more complex in an in vivo infection. Host-derived stresses and functional immune responses are known to drive an increase in heterogeneity in M. tuberculosis 7 . Furthermore, M. tuberculosis bacteria in activated host immune cells called phagocytes exhibit enhanced drug tolerance to frontline antituberculosis compounds compared wit h bacteria in nonactivated phagocytes 8 . One could speculate that the daughter cells generated by the action of LamA that had low calcein fluorescence could be at an advantage in dealing with both host-cell-induced stress and drug pressure in vivo.
The pathways to drug tolerance may differ in their underlying mechanisms, but the consequences are comparable. Drug tolerance caused by heterogeneity is probably a major driver of the evolution of heritable drug resistance 9 because heterogeneity and drug tolerance promote bacterial survival and thereby expand the window of opportunity for the acquisition of mutations that reduce antibiotic efficacy.
Although the prospects for developing successful treatments for tuberculosis remain daunting, understanding the biological basis of drug tolerance might open new avenues through which antibiotics could be used in combination with compounds that block the capacity of M. tuberculosis to promote heterogeneity or mobilize its drug-tolerance programs 10 . Drug-discovery approaches need to move beyond the landscape of target-based screening and embrace a discovery process that incorporates and tests the complex biology of bacterial heterogeneity and drug tolerance that occurs in vivo. ■ 
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